VICPLAS INTERNATIONAL LTD
(UEN 199805362R)
Incorporated in the Republic of Singapore
("**Company / VIL**")

MINUTES OF THE TWENTY-FOURTH ANNUAL GENERAL MEETING ("**AGM**" or "**Meeting**") OF THE COMPANY HELD BY ELECTRONIC MEANS PURSUANT TO THE COVID-19 (TEMPORARY MEASURES) (ALTERNATIVE ARRANGEMENTS FOR MEETINGS FOR COMPANIES, VARIABLE CAPITAL COMPANIES, BUSINESS TRUSTS, UNIT TRUSTS AND DEBENTURE HOLDERS) ORDER 2020 ON THURSDAY, THE 24TH DAY OF NOVEMBER 2022 AT 3.00 P.M.

Board of Directors
(attended in person and via live audio-visual webcast)

Mr. Yeo Wico	: Non-Executive Independent Chairman
Mr. Ng Cher Yan	: Non-Executive Independent Director
Mr. Ng Beng Tiong	: Non-Executive Independent Director
Mrs. Jane Rose Philomene Gaines-Cooper	: Non-Executive Director

(attended via live audio-visual webcast)

Mr. Christopher Paul Lee	: Non-Executive Director

Senior management (attended in person and via live audio-visual webcast)

Mr. Walter Tarca	: Group Chief Executive Officer and President of the Medical Devices Segment
Mr. Eric Cheng	: Managing Director of the Pipes and Pipe Fittings Segment
Mr. Jay Cheng	: Group Operations Director
Ms. Gan Ying Hui	: Chief Financial Officer

In attendance (attended via live audio-visual webcast)

Ms. Christine Chan	: Legal Adviser, Allen & Gledhill LLP
Ms. Celeste Yao	: Legal Adviser, Allen & Gledhill LLP
Ms. Kong Lai San	: Auditor, Deloitte & Touche LLP
Mr. Sim Keng Chong	: Internal Auditor, Foo Kon Tan LLP
Mr. Aw Eng Hai	: Internal Auditor, Foo Kon Tan LLP
Ms. Chew Pei Tsing	: Company Secretary

Shareholders (attended via live audio-visual webcast)
As set out in the attendance records maintained by the Company

1. Introduction

   The Chairman, Mr. Yeo Wico, welcomed the shareholders and attendees to the AGM. The Chairman introduced the members of the Board and the senior management team; the Company's legal adviser, auditor, internal auditor and the company secretary.

2. Quorum

   As a quorum was present, the Chairman called the AGM to order.

3. Notice

   The notice convening the AGM ("**Notice**"), proxy form, annual report and circular of the

Company were sent to the shareholders of the Company by electronic means via publication on the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on November 2, 2022 and were also made available on the Company's website. The Notice was taken as read.

4. Voting and "live" Q&A Session Procedures

The Chairman briefed the shareholders on the programme and administrative procedures for the Meeting. The Chairman elaborated that the shareholders and appointed proxies may raise questions, during a "live" question and answer ("**Q&A**") session which will take place following Management's presentation and before voting on the agenda items.

He further elaborated that the Q&A session will be a unified session during which the Company will address questions on all of the agenda items and hence no separate Q&A session will be held while each agenda item is being introduced and explained.

The Chairman then explained the voting procedures for this Meeting. He informed that voting will be conducted by poll in accordance with the listing rules and that all of the resolutions to be tabled for approval by shareholders at this AGM are Ordinary Resolutions. The Chairman also informed that shareholders and appointed proxies who are accessing the Meeting via the audio-visual webcast platform could cast their votes "live" at the Meeting, that is, by real-time remote electronic voting through the webcast platform.

The Chairman informed that in his capacity as the Chairman of the Meeting, he was appointed by some shareholders as their proxy, and he would vote in accordance with their instructions, where specified.

The Company had appointed B.A.C.S. Private Limited as the polling agent, Agile 8 Advisory Pte. Ltd. as the scrutineer and Convene SG Pte Ltd to facilitate "live" electronic voting for this Meeting. The Scrutineers verified and supervised the counting of votes of all such valid proxy forms submitted by shareholders by the submission deadline of 3.00p.m. on November 21, 2022, and verified the votes cast by the shareholders during the Meeting.

A short video explaining the "live" Q&A and "live" voting was played.

The voting function on the audio-visual webcast platform was then enabled for shareholders and appointed proxies to cast their votes during the course of the Meeting.

5. Corporate Presentation

Before proceeding with the business of the Meeting, a corporate presentation was presented by Mr. Walter Tarca, Mr. Jay Cheng and Ms. Gan Ying Hui. A copy of the Corporate presentation was published on the SGX-ST website on November 24, 2022 (Announcement Reference: SG221102MEET8P74) and a copy is also attached hereto.

The Chairman then proceeded to the items on the agenda for the AGM.

Ordinary Business

Ordinary Resolution No.1

6. Directors' Statement and Audited Financial Statements

The first item on the agenda was to receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended July 31, 2022 and the Auditor's Report thereon.

The Chairman proposed the following motion:

"That the Directors' Statement and the Audited Financial Statements of the Company for the year ended July 31, 2022 and the Auditors' Report thereon be received and adopted."

Ordinary Resolution No. 2

7. Final (one-tier tax exempt) dividend of S$0.0045 per share

The Chairman informed that the Directors had recommended a final (one-tier tax exempt) dividend of S$0.0045 per share for the year ended July 31, 2022. The proposed dividend, if approved by the shareholders at this Meeting, would be paid on January 20, 2023 to shareholders whose names appear in the Register of Members of the Company on January 11, 2023.

The Chairman proposed the following motion:

"That a final (one-tier tax exempt) dividend of S$0.0045 per share for the year ended July 31, 2022 be declared payable on January 20, 2023 to shareholders whose names appear in the Register of Members of the Company on January 11, 2023."

Ordinary Resolution No. 3

8. Directors' Fees

The Chairman proposed the following motion:

"That the payment of S$300,000 as fees to the Directors of the Company for the year ended July 31, 2022 be approved."

Ordinary Resolution No. 4

9. Re-election of Mrs. Jane Rose Philomene Gaines-Cooper as a Director of the Company

The Chairman informed that Mrs. Jane Rose Philomene Gaines-Cooper was retiring as a Director by rotation in accordance with Article 115 of the Company's Constitution. Mrs. Jane Rose Philomene Gaines-Cooper, being eligible, offered herself for re-election. The Nominating Committee (with Mrs. Gaines-Cooper abstaining) had recommended that Mrs. Gaines-Cooper be re-elected. Mrs. Gaines-Cooper, if re-elected, would continue as a member of the Nominating Committee, Remuneration Committee and Strategy Committee of the Company.

The Chairman proposed the following motion:

"That Mrs. Jane Rose Philomene Gaines-Cooper be re-elected as a Director of the Company."

10. Retirement of Mr. Christopher Paul Lee as a Director of the Company

The Chairman informed that Mr. Christopher Paul Lee retired at this AGM by rotation in accordance with Article 115 of the Company's Constitution and he had decided not to seek re-election. Mr. Lee's retirement from the Board would take effect from the conclusion of this AGM and he would also cease to be Chairman of the Strategy Committee concurrently.

On behalf of the Board and Management, the Chairman expressed appreciation and thanked Mr. Lee for his service and contribution to the Board during his tenure.

Ordinary Resolution No. 5

11. Re-appointment of Auditor

The Chairman informed that the Auditors, Deloitte & Touche LLP have expressed its willingness to accept re-appointment as the Company's Auditor for the ensuing year and the Audit and Risk Committee had recommended that it be re-appointed at this Meeting.

The Chairman proposed the following motion:

"That Deloitte & Touche LLP be re-appointed as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and that the Directors be authorised to fix its remuneration."

Special Business

Ordinary Resolution No. 6

12. Authority to allot and issue shares and convertible instruments

The Chairman informed that pursuant to Section 161 of the Companies Act 1967 and the listing rules of the SGX-ST, shareholders' approval is required to authorise the Directors of the Company to issue new shares and/or make or grant instruments convertible into shares up to the limits specified, as set out in Resolution 6 of the Notice, and that such authority is refreshed annually at the AGM.

The Chairman proposed the motion as set out in Resolution 6 of the Notice.

Ordinary Resolution No. 7

13. Renewal of the Interested Person Transactions ("**IPT**") Mandate

The Chairman informed that the Company is seeking the shareholders' approval for the proposed renewal of the IPT mandate on the terms as set out in Resolution 7 of the Notice. Details of the IPT Mandate were set out in the Appendix to the Company's Circular to shareholders dated November 2, 2022.

The Chairman proposed the motion as set out in Resolution 7 of the Notice.

Ordinary Resolution No. 8

14. Renewal of the Share Purchase Mandate

The Chairman informed that the Company is seeking the shareholders' approval for the proposed renewal of the Share Purchase Mandate on the terms as set out in Resolution 8 of the Notice. Details of the Share Purchase Mandate were set out in the

Circular to the shareholders dated November 2, 2022.

The Chairman proposed the motion as set out in Resolution 8 of the Notice.

Ordinary Resolution No. 9

15. Authority to grant options, and allot and issue shares, pursuant to the Vicplas International Share Option Plan 2021 ("**VISOP 2021**")

The Chairman informed that the Company is seeking the shareholders' approval to authorise the Directors to grant options, and to allot and issue ordinary shares of the Company pursuant to the exercise of options under the Vicplas International Share Option Plan 2021, on the terms as set out in Resolution 9 of the Notice.

The Chairman proposed the motion as set out in Resolution 9 of the Notice.

Ordinary Resolution No. 10

16. Authority to issue new shares pursuant to the Vicplas International Ltd Scrip Dividend Scheme

The Chairman informed that the Company is seeking the shareholders' approval to authorise the Directors to allot and issue ordinary shares of the Company pursuant to the Vicplas International Ltd Scrip Dividend Scheme in accordance with Resolution 10 of the Notice.

The Chairman proposed the motion as set out in Resolution 10 of the Notice.

17. Live "Q&A"

After presenting all the agenda items, the Chairman opened the floor for the "live" Q&A session.

There were no questions received from shareholders of the Company during the "live" Q&A session.

18. Voting

The Chairman then proceeded to put all the motions which have been tabled at the Meeting to vote by poll.

At the end of the voting period, the Chairman declared the "live" voting closed.

19. Poll results

The poll voting results duly certified by the Scrutineer are as follows:

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
Ordinary Business					
Ordinary Resolution 1 To receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the year ended July 31, 2022 and the Auditor's Report thereon.	333,881,802	333,881,802	100.00	0	0.00
Ordinary Resolution 2 To declare a final (one-tier tax exempt) dividend of S$0.0045 per share for the year ended July 31, 2022.	333,881,802	333,881,802	100.00	0	0.00

Ordinary Resolution 3 To approve the Directors' fees of S$300,000.00 for the year ended July 31, 2022.	333,881,802	333,881,802	100.00	0	0.00
Ordinary Resolution 4 To re-elect Mrs. Jane Rose Philomene Gaines-Cooper as a Director pursuant to Article 115 of the Company's Constitution.	333,881,802	333,881,802	100.00	0	0.00
Ordinary Resolution 5 To re-appoint Deloitte & Touche LLP as Auditor and to authorise the Directors to fix its remuneration.	333,881,802	333,881,802	100.00	0	0.00
Special Business					
Ordinary Resolution 6 To authorise the Directors to issue additional shares and convertible instruments.	333,881,802	333,737,802	99.96	144,000	0.04

Ordinary Resolution 7 To approve the renewal of the Interested Person Transactions Mandate.	29,031,161	29,031,161	100.00	0	0.00
Ordinary Resolution 8 To approve the renewal of the Share Purchase Mandate.	333,881,802	333,881,802	100.00	0	0.00
Ordinary Resolution 9 To authorise the grant of options and the allotment and issuance of shares pursuant to the Vicplas International Share Option Plan 2021.	281,108,877	280,964,877	99.95	144,000	0.05
Ordinary Resolution 10 To authorise the issuance of shares pursuant to the Vicplas International Ltd Scrip Dividend Scheme.	333,881,702	333,881,702	100.00	0	0.00

Based on the poll voting results, the Chairman declared that all the Resolutions tabled at the Meeting were carried.

20. Conclusion

There being no other business, the Chairman declared the AGM closed at 3.52 p.m and thanked all for attending the AGM.

CONFIRMED AS A RECORD OF THE PROCEEDINGS OF THE MEETING

YEO WICO
CHAIRMAN



VICPLAS INTERNATIONAL LTD

The parent company of
Forefront Medical and Vicplas Holdings

FOREFRONT

VICPLAS


Corporate Presentation
FY2022 Results

DISCLAIMER

This presentation is for information purposes only and does not constitute or form part of an offer, solicitation, recommendation or invitation for the sale or purchase or subscription of securities in Vicplas International Ltd (the "Company" or "Vicplas"). No part of it nor the fact of its presentation shall form the basis of or be relied upon in connection with any investment decision, contract or commitment whatsoever.

The information and opinions in this presentation are provided as at the date of this document (unless stated otherwise) and are subject to change without notice, their accuracy are not guaranteed, represented or warranted and they may not contain all material or relevant information concerning the Company or the Company and its subsidiaries (collectively, the "Group"). Neither the Company nor its related corporations, affiliates, nor any of their respective directors, officers, partners, employees, agents, representatives or advisers make any representation or warranty regarding, and assumes no responsibility, obligation or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of this presentation. Further, nothing in this presentation should be construed as constituting legal, business, tax, investment or financial advice.

The information contained in this presentation includes historical information about and relevant to the Group or the Group's businesses that should not be regarded as an indication of the future performance or results of the Group or such businesses. Certain statements in this presentation constitute "forward-looking statements". These forward-looking statements are based on the current views of the Group concerning future events, and necessarily involve risks, uncertainties and assumptions, which may change over time. These statements can be recognised by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends" or words of similar meaning. Actual future performance could differ materially from these forward-looking statements, and no assurance is given that future events will occur, that projections will be achieved, or that the Group's views are correct, nor should you rely on these forward-looking statements for any purpose. The Company does not assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise, subject to compliance with all applicable laws and regulations and/or the rules of the Singapore Exchange Securities Trading Limited and/or any other regulatory or supervisory body or agency.



CONTENTS

About Us

COMPANY OVERVIEW

FINANCIAL INFORMATION

Our Companies

FOREFRONT MEDICAL

VICPLAS HOLDINGS


COMPANY OVERVIEW

VICPLAS INTERNATIONAL LTD





GLOBAL PRESENCE



Business Segments

Medical devices segment

Forefront Medical designs, develops and manufactures sterile and non-sterile medical devices

Pipes & pipe fittings segment

Vicplas Holdings ("Vicplas Pipes") manufactures and distributes piping systems for diverse industries


Total employees : 1,000+ worldwide

Accreditations

The subsidiaries in the pipes and pipe fittings segment have ISO9001:2015 quality certifications. Vicplas Holdings Pte Ltd additionally is ISO5001:2018, ISO14001:2015 and ISO45001:2018 certified.
The subsidiaries in the medical devices segment have EN ISO13485:2016 quality certifications and with the exception of XentiQ (Pte.) Ltd., are registered under the United States Food and Drug Administration (FDA) as a "contract manufacturer for medical devices" and Accreditation certificate of foreign medical device manufacturer from Japan Ministry of Health, Labour and Welfare. Forefront Medical Investments Pte. Ltd. additionally has a Class A, B, C, D Medical Device manufacturer license registered under Health Science Authority (HAS) Singapore and Forefront Medical Technology (Jiangsu) Co., Ltd additionally has a Class II Medical Device Manufacturing License in China.

FINANCIAL INFORMATION

VICPLAS INTERNATIONAL LTD



FY2022 FINANCIAL OVERVIEW

Group revenue grew by 14.8% and net profit after tax fell by 15.0% compared to FY2021, affected by rising supply chain costs and other disruptions caused by the Covid-19 pandemic.

Adjusted EBITDA reduced by only 1.5% to S$18.3M compared to FY2021. The Group is continuing to invest intensively, in particular to increase the global manufacturing footprint for the medical devices segment.

Medical devices segment continues positive growth momentum with segmental revenue growing by 15.5% although segmental results fell by 15.3% compared to FY2021.

Pipes and pipe fitting segmental revenue improved by 13.1% in FY2022 and segmental results improved by 42.0% as compared to FY2021.

Group

S$'000	FY2022	FY2021	% Change
Revenue	**130,808**	113,945	14.8
Profit before Tax	**11,006**	12,304	-10.5
Net Profit after Tax	**8,839**	10,403	-15.0
Net Profit Margin	**6.8%**	9.1%	-2.3
Adjusted EBITDA[1]	**18,299**	18,585	-1.5

Segment

S$'000		FY2022	FY2021	% Change
Medical Devices	**Revenue**	**92,601**	80,166	15.5
	Segmental Results[2]	**10,229**	12,073	-15.3
Pipes & Pipe Fittings	**Revenue**	**38,207**	33,779	13.1
	Segmental Results[2]	**4,503**	3,172	42.0

[1] Adjusted EBITDA refers to earnings before interest, tax, depreciation and amortization; and excludes unrealised foreign exchange.
[2] The segmental results of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 4 of the Condensed Interim Financial Statements.


REVENUE GROWTH

Over the past five financial years, we achieved steady revenue growth with a CAGR of 16.8%. Growth is expected to continue, but the rate of growth can be expected to moderate with a higher base.

Forefront Medical's contribution to Group revenue continues to grow as the Group steadily transforms into a medical device-focused group.


Vicplas Pipes, an industry leader in the mature pipes and pipe fittings segment, is seeing a recovery alongside the construction industry in Singapore. With a manufacturing presence in Singapore, it is well positioned to support customers as the domestic construction industry continues its growth momentum.

Vicplas Pipes provides a stable foundation while Forefront Medical pursues accelerated growth in the growing medical devices segment.



PROFIT GROWTH


For FY2022, our net margin has been affected by increased raw material and energy costs, higher headcount and repairs & maintenance costs to support the higher revenue, higher tax expense, as well as the non-recurrence of Covid-19 related government subsidies.



SEGMENTAL RESULTS – FOREFRONT MEDICAL

Forefront Medical continues its growth momentum of recent years with increased orders from its customers.

Posted a strong segmental result* which was impacted by rising supply chain costs and other disruptions caused by the Covid-19 pandemic, as well as higher costs associated with business expansion through increasing manufacturing plant capacity, and onboarding additional technical and business development resources.




*The segmental results of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 4 of the Condensed Interim Financial Statements.

SEGMENTAL RESULTS – VICPLAS PIPES

Vicplas Pipes' FY2022 revenue improved alongside the recovery of the construction industry in Singapore.

Segmental result* for FY2022 showed a marked improvement, despite higher material and overheads cost



*The segmental results of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 4 of the Condensed Interim Financial Statements.

MEDICAL DEVICES

Walter Tarca
President

FOREFRONT
MEDICAL

WWW.FOREFRONTMEDICAL.COM

OUR VISION

To be a leading global medical device manufacturing partner with solutions that are preferred by product owners

- 100% focused on manufacturing quality devices for the medical device industry
- Global customer base in five continents
- More than 900 employees
- Committed to providing our customers and their patients with innovative and cost-effective medical devices to enable continuous improvements in healthcare





Singapore – Corporate HQ



Changzhou, China



Xiamen, China



GLOBAL PRESENCE

Manufacturing Sites

- Singapore – Corporate HQ (7,410m^2)
- Xiamen, China (7,000m^2)
- Changzhou, China (7,024m^2 + 7,000m^2 extension)
- Kington, UK (2,600m^2)

Commercial Offices

- Singapore
- Shanghai, China
- Connecticut, USA
- Kington, UK


OPPORTUNITIES

A GROWING INDUSTRY

The MedTech contract manufacturing market is expected to grow by an average of 11.4% year-on-year through 2025.

Key drivers:

- Ageing population
- Increased demand for improved healthcare in developing markets
- Increased willingness by product owners to outsource manufacturing to trusted partners that can fully support product and process innovation



https://www.meddeviceonline.com/doc/pocket-guide-to-medtech-s-market-outlook-in-0001
https://www.meddeviceonline.com/doc/trends-in-medical-device-contract-manufacturing-what-medtech-oems-need-to-know-0001

FOREFRONT

OUR MEDICAL DEVICE PORTFOLIO

- Vascular
- Pharmaceutical Bottles
- Surgical Devices
- Respiratory
- Orthodontics
- Airway Management
- PPE Gowns / Nasal Swabs
- Endoscopy
- Drug Delivery
- Diagnostics



EXTENSIVE IN-HOUSE CAPABILITIES

FROM CONCEPT TO MANUFACTURING



PediGuard for Spinal Surgery



Feeding PVC Tube with Tungsten



Laryngeal Mask with LSR Cuff



Reinforced Extruded Silicone Tube

Design & Development	• Product Concept & Realisation • Electronics, Software, Metal Parts	
Rapid Prototyping		
Plastic & LSR Tooling	• In-house Toolroom & Design Team • Insert Mould	• Micro Mould • 2K Mould • Stack Mould
Moulding Capabilities	• Wide Range of Materials • Injection • Extrusion	• Injection Blow • Extrusion Blow
Production	• Cleanroom Facility • Pilot/Trial Run	• Low Mix High Volume • High Mix Low Volume
Quality	• ISO 13485 • FDA 510K	• CE Mark • IQ/OQ/PQ
Assembly	• Manual Assembly • High Speed Automation	
Secondary Processes	• Hydrophilic Coating • RF Tipping & Forming	• Pad Printing • Bonding & Welding
Packing	• Rigid Blister • Soft Blister	• Tyvek Pouch • Pallet Optimisation
Sterillization	• EtO • Gamma	• Autoclave • E-Beam

FOREFRONT

FY2022 HIGHLIGHTS


- Continued efforts to build a company that is resourceful, flexible and resilient to build long term partnerships and sustainability for our stakeholders
- The segment improved on performance in FY2022 with a revenue growth increase of 15.5% notwithstanding disruptions and delays arising from the Covid-19 pandemic
- The segmental result of S$10.2M was affected by rising supply chain costs and other disruptions caused by Covid-19 pandemic, as well as higher business expansion costs due to increased manufacturing capacity and onboarding of additional technical and business development resources to meet current and future demand
- Changzhou plant extension was completed at the end of FY2022 and additional revenues from the extended footprint expected in the first half of FY23
- Newly awarded projects continued to be commercialised and will feed into the revenue stream in the next few years and continued to expand global customer base



ACHIEVING OUR VISION


OUR STRATEGIC INTENT

To improve profitability by delivering great solutions for our customers and building sustainable value for all our stakeholders



FINANCIAL RESULTS

SUSTAINED YEAR-ON-YEAR SALES GROWTH



OUR STRATEGIC PRIORITIES

1. ACCELERATE CAPITAL INVESTMENTS

- Broaden global footprint to satisfy demand and improve flexibility for new customers
  - Changzhou extension completed
  - Juarez, Mexico Plant
- Implement factory I.4 initiatives to drive operational efficiency improvements

2. DRIVE CAPABILITY IMPROVEMENTS & INNOVATION

- Build expanded capabilities in medical extrusions ,in-vitro diagnostics and electro-mechanical devices to strengthen new revenue streams
- Continued investment in collaborative projects with MedTech product owners to expand our capabilities and drive growth

3. BUILD A HIGH-PERFORMANCE TEAM TO DRIVE GROWTH

- Continue to develop and provide opportunities for our highly engaged, tenured team
- Invest in additional MedTech talent pool to drive new revenue streams and manage growth

REVENUE GROWTH MOMENTUM

BUSINESS OUTLOOK

- Continue to be optimistic about long-term growth opportunities in medical device manufacturing globally because of expected market growth and our increasing capability
- Optimism must be tempered by caution in the face of a macro environment of some uncertainty due to current international trading conditions and inflationary pressures
- Positive revenue momentum to continue as segment grows its customer base coupled with planned improvements to product mix, plant efficiency and utilisation
- Forefront continues to invest intensively as it scales up its global footprint to meet both current and future customer demand. Plan to invest in its fifth manufacturing location in Mexico to provide operational diversity, additional space to meet growth expectations and resilience for our customer base.

PIPES & PIPE FITTINGS

Jay Cheng
Group Operations Director

VICPLAS
PIPES

WWW.VICPLAS.COM.SG

A SUSTAINABLE BUSINESS

ABOUT US

Vicplas Pipes is a leading solutions provider in the plastic pipe manufacturing industry. Our uPVC piping systems are found in a majority of residential homes across Singapore. Our market leadership is built on the quality and reliability of our products. They are commonly found in:

- **Plumbing and Electrical Works** across residential, commercial, institutional, industrial and other buildings
- **Civil Engineering Works** ranging from telecommunication and power grid pipelines to infrastructure works

VICPLAS

OUR VALUE PROPOSITION TO CUSTOMERS

Solutions Provider

Proactively look for new product development opportunities to fill industry gaps and meet emerging needs

Operational Efficiency

Invest in new technologies and improve existing processes to enhance operational and manufacturing efficiency



Product Reliability

Conduct regular quality checks to ensure that our products meet our stringent quality standards and applicable regulatory requirements

Green Initiatives


Contribute to a cleaner and greener future by developing environmentally friendly products

Research & Development

Constantly explore new possibilities in the design and manufacture of our products


VICPLAS

OUR CORE CAPABILITIES



Product Design

Develop practical, cost-efficient solutions that evolve with the changing needs of our customers.



Processing Techniques

Proficient across a range of polymer processing techniques and are able to offer injection, extrusion, thermal forming and fabrication processes.



Tool Fabrication

Equipped with in-house mould design and fabrication capabilities.



Materials Know-how

Extensive working knowledge of polymeric materials such as engineering plastics, specialty elastomers, composites and more.

Vicplas Pipes' products are all certified by international testing bodies to meet the industry standards of product quality.

SETSCO SGS TÜV SÜD

VICPLAS

PRODUCT APPLICATIONS



BUILDINGS

Residential homes
Commercial buildings
Institutional buildings
Industrial / Others



CIVIL ENGINEERING

Telecommunication pipelines
Power grid pipelines
Infrastructure works

HYDRO-AGRICULTURE

Plastic pipes
Plastic channels



VICPLAS

FY2022 HIGHLIGHTS

- FY2022 revenue increased by 13.1% alongside recovery of Singapore's construction industry from disruptions caused by Covid-19 pandemic

- Segmental result for FY2022 improved by 42.0% from FY2021 despite higher material and overheads costs

- While the segment expects higher revenue from the brightened outlook, it continues to face increasing competition and cost pressures



VICPLAS

BUSINESS OUTLOOK

OPPORTUNITIES AMIDST CHALLENGING ENVIRONMENT

- Well positioned to support customers with its local manufacturing presence as Singapore's construction industry continues its growth momentum
- SGBC Green Check Marks certification paves the way for opportunities for piping systems adopted in green buildings

PRUDENT AND FOCUSED GROWTH

- Continue to operate prudently and drive operational efficiencies through continuous improvement
- Focused on pipeline of civil engineering projects relating to the building of new townships in Singapore as more public housing units are expected to be released over the next few years

VICPLAS

THANK YOU

Vicplas International Ltd
Reg No: 199805362R
www.vicplas.com